References
- Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77–106. doi:https://doi.org/10.1016/j.gendis.2018.05.001
- Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: Exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer. 2006;13(Supplement_1):S15–S24. doi:https://doi.org/10.1677/erc.1.01273
- Huang P-H, Huang C-Y, Chen M-C, Lee Y-T, Yue C-H, Wang H-Y, Lin H. Emodin and Aloe-Emodin suppress breast cancer cell proliferation through ER α inhibition. Evid Based Complement Alternat Med. 2013;2013:376123. doi:https://doi.org/10.1155/2013/376123
- Lee D, Park S, Choi S, Kim SH, Kang KS. In vitro estrogenic and breast cancer inhibitory activities of chemical constituents isolated from Rheum undulatum L. Molecules. 2018;23(5):1215. doi:https://doi.org/10.3390/molecules23051215
- Shrimali D, Shanmugam MK, Kumar AP, Zhang J, Tan BKH, Ahn KS, Sethi G. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 2013;341(2):139–149. doi:https://doi.org/10.1016/j.canlet.2013.08.023
- Wei WT, Lin SZ, Liu DL, Wang ZH. The distinct mechanisms of the antitumor activity of emodin in different types of cancer (review). Oncol Rep. 2013;30(6):2555–2562. doi:https://doi.org/10.3892/or.2013.2741
- Jayasuriya H, Koonchanok NM, Geahlen RL, Mclaughlin JL, Chang CJ. Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum. J Nat Prod. 1992;55(5):696–698. doi:https://doi.org/10.1021/np50083a026
- Zhang L, Lau YK, Xi L, Hong RL, Kim DS, Chen CF, Hortobagyi GN, Chang C, Hung MC. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene. 1998;16(22):2855–2863. doi:https://doi.org/10.1038/sj.onc.1201813
- Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res. 1999;5(2):343–353.
- Song X, Zhou X, Qin Y, Yang J, Wang Y, Sun Z, Yu K, Zhang S, Liu S. Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes. Int J Mol Med. 2018;42(1):579–588. doi:https://doi.org/10.3892/ijmm.2018.3638
- Sui JQ, Xie KP, Zou W, Xie MJ. Emodin inhibits breast cancer cell proliferation through the ERα-MAPK/Akt-Cyclin D1/Bcl-2 signaling pathway. Asian Pac J Cancer Prev. 2014;15(15):6247–6251. doi:https://doi.org/10.7314/apjcp.2014.15.15.6247
- Cheshmi F, Kazerouni F, Omrani MD, Rahimipour A, Shanaki M, Dehghan -Nayeri N, Younesian O, Rezapour Kalkhoran M. Effect of emodin on expression of VEGF-A and VEGFR_2 genes in human breast carcinoma MCF-7 cell. Int J Cancer Manag. 2017;10(7):e8095. doi:https://doi.org/10.5812/ijcm.8095
- Huang Z, Chen G, Shi P. Emodin-induced apoptosis in human breast cancer BCap-37 cells through the mitochondrial signaling pathway. Arch Pharm Res. 2008;31(6):742–748. doi:https://doi.org/10.1007/s12272-001-1221-6
- Li WY, Chan RYK, Yu PHF, Chan SW. Emodin induces cytotoxic effect in human breast carcinoma MCF-7 cell through modulating the expression of apoptosis-related genes. Pharm Biol. 2013;51(9):1175–1181. doi:https://doi.org/10.3109/13880209.2013.782322
- Zu C, Zhang M, Xue H, Cai X, Zhao L, He A, Qin G, Yang C, Zheng X. Emodin induces apoptosis of human breast cancer cells by modulating the expression of apoptosis-related genes. Oncol Lett. 2015;10(5):2919–2924. doi:https://doi.org/10.3892/ol.2015.3646
- Zu C, Qin G, Yang C, Liu N, He A, Zhang M, Zheng X. Low dose Emodin induces tumor senescence for boosting breast cancer chemotherapy via silencing NRARP. Biochem Biophys Res Commun. 2018;505(4):973–978. doi:https://doi.org/10.1016/j.bbrc.2018.09.045
- Guo J, Li W, Shi H, Xie X, Li L, Tang H, Wu M, Kong Y, Yang L, Gao J, et al. Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Mol Cell Biochem. 2013;382(1-2):103–111. doi:https://doi.org/10.1007/s11010-013-1723-6
- Ma J, Lu H, Wang S, Chen B, Liu Z, Ke X, Liu T, Fu J. The anthraquinone derivative Emodin inhibits angiogenesis and metastasis through downregulating Runx2 activity in breast cancer. Int J Oncol. 2015;46(4):1619–1628. doi:https://doi.org/10.3892/ijo.2015.2888
- Sun Y, Wang X, Zhou Q, Lu Y, Zhang H, Chen Q, Zhao M, Su S. Inhibitory effect of emodin on migration, invasion and metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo. Oncol Rep. 2015;33(1):338–346. doi:https://doi.org/10.3892/or.2014.3585
- Sakallı E. Comparative effects of emodin on biological activities of MCF-7 and MDA-231 cell lines [M.Sc. Thesis]. Ankara: Middle East Technical University; 2010.
- Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001;29(4):365–371. doi:https://doi.org/10.1038/ng1201-365
- Simon R, Lam A, Li M-C, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-array tools. Cancer Inform. 2007;3:11–17. doi:https://doi.org/10.1177/117693510700300022
- Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, Vilo J. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47(W1):W191–W198. doi:https://doi.org/10.1093/nar/gkz369
- Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, et al. The GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(Web Server issue):W214–W220. doi:https://doi.org/10.1093/nar/gkq537
- Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613. doi:https://doi.org/10.1093/nar/gky1131
- Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: A network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010;5(11):e13984. doi:https://doi.org/10.1371/journal.pone.0013984
- Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: A software environment for integrated0 models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:https://doi.org/10.1101/gr.1239303
- Marques S, Fonseca J, Silva PM, Bousbaa H. Targeting the spindle assembly checkpoint for breast cancer treatment. Curr Cancer Drug Targets. 2015;15(4):272–281. doi:https://doi.org/10.2174/1568009615666150302130010
- Bolanos-Garcia VM, Blundell TL. BUB1 and BUBR1: multifaceted kinases of the cell cycle. Trends Biochem Sci. 2011;36(3):141–150. doi:https://doi.org/10.1016/j.tibs.2010.08.004
- Ji Z, Gao H, Jia L, Li B, Yu H. A sequential multi-target Mps1 phosphorylation cascade promotes spindle checkpoint signaling. eLife. 2017;6:e22513. doi:https://doi.org/10.7554/eLife.22513
- Fu Z, Tindall DJ. FOXOs, cancer and regulation of apoptosis. Oncogene. 2008;27(16):2312–2319. doi:https://doi.org/10.1038/onc.2008.24
- Gross DN, Wan M, Birnbaum MJ. The role of FOXO in the regulation of metabolism. Curr Diab Rep. 2009;9(3):208–214. doi:https://doi.org/10.1007/s11892-009-0034-5
- Obsil T, Obsilova V. Structure/function relationships underlying regulation of FOXO transcription factors. Oncogene. 2008;27(16):2263–2275. doi:https://doi.org/10.1038/onc.2008.20
- Liu Z, Ren YA, Pangas SA, Adams J, Zhou W, Castrillon DH, Wilhelm D, Richards JS. FOXO1/3 and PTEN depletion in granulosa cells promotes ovarian granulosa cell tumor development. Mol Endocrinol. 2015;29(7):1006–1024. doi:https://doi.org/10.1210/me.2015-1103
- Goto T, Takano M, Albergaria A, Briese J, Pomeranz KM, Cloke B, Fusi L, Feroze-Zaidi F, Maywald N, Sajin M, et al. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene. 2008;27(1):9–19. doi:https://doi.org/10.1038/sj.onc.1210626
- Dong X-Y, Chen C, Sun X, Guo P, Vessella RL, Wang R-X, Chung LWK, Zhou W, Dong J-T. FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res. 2006;66(14):6998–7006. doi:https://doi.org/10.1158/0008-5472.CAN-06-0411
- Yan H, Wu A. FOXO1 is crucial in glioblastoma cell tumorigenesis and regulates the expression of SIRT1 to suppress senescence in the brain. Mol Med Rep. 2018;17:2535–2542.
- Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 2009;284(35):23204–23216. doi:https://doi.org/10.1074/jbc.M109.031427
- Reagan-Shaw S, Ahmad N. RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells . Cancer Res. 2006;66(2):1062–1069. doi:https://doi.org/10.1158/0008-5472.CAN-05-1018
- Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res. 2001;61(16):5985–5991.
- Sheikh MS, Rochefort H, Garcia M. Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene. 1995;11(9):1899–1905.
- Carroll JS, Prall OWJ, Musgrove EA, Sutherland RL. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem. 2000;275(49):38221–38229. doi:https://doi.org/10.1074/jbc.M004424200
- Katagi A, Sui L, Kamitori K, Suzuki T, Katayama T, Hossain A, Noguchi C, Dong Y, Yamaguchi F, Tokuda M, et al. Inhibitory effect of isoamericanol A from Jatropha curcas seeds on the growth of MCF-7 human breast cancer cell line by G2/M cell cycle arrest. Heliyon. 2016;2(1):e00055. doi:https://doi.org/10.1016/j.heliyon.2015.e00055
- Farhan M, Wang H, Gaur U, Little PJ, Xu J, Zheng W. FOXO signaling pathways as therapeutic targets in cancer. Int J Biol Sci. 2017;13(7):815–827. doi:https://doi.org/10.7150/ijbs.20052
- Hartog H, Van Der Graaf WT, Boezen HM, Wesseling J. Treatment of breast cancer cells by IGF1R tyrosine kinase inhibitor combined with conventional systemic drugs. Anticancer Res. 2012;32(4):1309–1318.
- Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci. 2007;120(Pt 15):2479–2487. doi:https://doi.org/10.1242/jcs.001222
- Wang Z, Fukushima H, Inuzuka H, Wan L, Liu P, Gao D, Sarkar FH, Wei W. Skp2 is a promising therapeutic target in breast cancer. Front Oncol. 2011;1:57.
- Al-Ejeh F, Simpson PT, Saunus JM, Klein K, Kalimutho M, Shi W, Miranda M, Kutasovic J, Raghavendra A, Madore J, et al. Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis. 2014;3:e124. doi:https://doi.org/10.1038/oncsis.2014.41
- Du J, Du Q, Zhang Y, Sajdik C, Ruan Y, Tian X-X, Fang W-G. Expression of cell-cycle regulatory proteins BUBR1, MAD2, Aurora A, cyclin A and cyclin E in invasive ductal breast carcinomas. Histol Histopathol. 2011;26:761–768.
- Han JY, Han YK, Park GY, Kim SD, Lee CG. Bub1 is required for maintaining cancer stem cells in breast cancer cell lines. Sci Rep. 2015;5:15993. doi:https://doi.org/10.1038/srep15993
- Karra H, Repo H, Ahonen I, Löyttyniemi E, Pitkänen R, Lintunen M, Kuopio T, Söderström M, Kronqvist P. Cdc20 and securin overexpression predict short-term breast cancer survival. Br J Cancer. 2014;110(12):2905–2913. doi:https://doi.org/10.1038/bjc.2014.252
- Maciejczyk A, Szelachowska J, Czapiga B, Matkowski R, Hałoń A, Györffy B, Surowiak P. Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis. J Histochem Cytochem. 2013;61(5):330–339. doi:https://doi.org/10.1369/0022155413480148
- Maia ARR, de Man J, Boon U, Janssen A, Song J-Y, Omerzu M, Sterrenburg JG, Prinsen MBW, Willemsen-Seegers N, de Roos JADM, et al. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. Ann Oncol. 2015;26(10):2180–2192. doi:https://doi.org/10.1093/annonc/mdv293
- Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L, Rigaill G, Dumont A, et al. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS One. 2013;8(5):e63712. doi:https://doi.org/10.1371/journal.pone.0063712
- Takagi K, Miki Y, Shibahara Y, Nakamura Y, Ebata A, Watanabe M, Ishida T, Sasano H, Suzuki T. BUB1 immunolocalization in breast carcinoma: Its nuclear localization as a potent prognostic factor of the patients. Horm Cancer. 2013;4(2):92–102. doi:https://doi.org/10.1007/s12672-012-0130-x